Nika Pharmaceuticals Reports Q2 2026 Financial Results with Increased Net Loss

Nika Pharmaceuticals, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $19,694 for the three months ended June 30, 2026, compared to a net loss of $18,381 for the same period in 2025. The company has not generated any revenue during this period, maintaining a consistent trend of no income. Total operating expenses increased to $19,694 from $18,381 year-over-year, primarily driven by higher general and administrative costs, which rose to $14,848 from $14,300. Professional fees also saw an increase, totaling $4,846 compared to $4,081 in the prior year.

In terms of financial position, Nika Pharmaceuticals reported total current assets of $9,942 as of June 30, 2026, a significant decrease from $20,996 at the end of 2025. The company's cash reserves increased to $2,932 from $1,889, while prepaid expenses dropped sharply from $19,107 to $7,010. The total liabilities stood at $340,624, up from $318,624, reflecting ongoing financial obligations primarily to related parties. The accumulated deficit increased to $9,037,063 from $9,004,009, indicating a continued struggle with profitability.

Strategically, Nika Pharmaceuticals has been active in expanding its operations and product offerings. The company completed a merger with Nika BioTechnology, Inc. in April 2024, which enhanced its stake in Nika Europe, Ltd. to 80%. This merger is part of a broader strategy to establish a manufacturing presence in Europe, Asia, and Africa, with plans for a pharmaceutical factory that will produce various drug forms. Additionally, Nika has entered into multiple exclusive rights agreements for the production and distribution of dietary supplements and other pharmaceutical products, aiming to broaden its market reach.

Operationally, the company has not reported significant changes in customer counts or user statistics, as it continues to focus on establishing its product lines. The employee headcount remains stable, with no new hires reported in the latest filing. Nika's market share remains limited due to its current lack of revenue generation and ongoing financial challenges. The company has relied on loans from related parties to fund its operations, receiving $22,000 in loans during the first half of 2026, down from $45,000 in the same period of 2025.

Looking ahead, Nika Pharmaceuticals acknowledges substantial doubt about its ability to continue as a going concern, given its accumulated deficit and lack of revenue. The company plans to raise additional capital through equity and debt offerings to support its operations. Management has indicated that while the financial outlook remains uncertain, they are committed to executing their strategic initiatives to enhance the company's market position and operational capabilities.